Geoff Martha has been CEO of the world’s largest medical device maker for nearly 21 months, amid the massive external turmoil and major internal setbacks caused by Covid.
Against this backdrop, Martha attended the 40th annual JPMorgan Chase Healthcare Conference on Monday, virtually explaining key decisions, taking responsibility for three barrages of bad news, while also hinting at the Dublin-based medtech Everything will be fine for the giant in the future. Here are some highlights from his presentation and Q&A.
Martha responds to setback and recalls massive
Medtronic recently suffered setbacks in three businesses, and Martha admitted he was responsible for those failures.
First, on October 15th, Company revealed Its renal denervation system to reduce resistant hypertension failed to resist sham surgery. Previously, the company had expected the efficacy of Symplicity’s renal denervation system to be so strong that the trial could be stopped early, speeding up regulatory approval of the device. The full enrollment of the trial will now be conducted, and more data analysis will determine whether the system can indeed lower blood pressure in patients who are taking three blood pressure medications but still have high blood pressure.
This is not the first time the renal nervous system has been removed experienced an embarrassing setbackBack in January 2014, the company’s pivotal Symplicity HTN-3 trial did not meet its primary safety endpoint, with patients in the control group benefiting from a larger placebo effect.Then in the spring of 2015, Medtronic said it was try again Its next-generation renal denervation system initiated two global studies. With renal denervation, gentle electrical pulses are used to stimulate the renal nerves to reduce stubborn high blood pressure.
Medtronic’s second recent failure is related to its Hugo surgical robotic system. On the Nov. 23 earnings call, Martha had to admit that the wider launch of the product was behind schedule, which would lead to lower revenue — the company expects revenue for the current fiscal year if Hugo’s launch continues on schedule At the time, Martha said the problems stemmed from manufacturing and supply chain issues and were not a reflection of actual customer needs. On Monday’s conference call, Martha reiterated that customers are still interested.
The third disappointing news is Warning Letter From the Food and Drug Administration of Medtronic’s diabetes division, the company announced in mid-December. The letter alleges that the Northbridge, California facility, which serves as the headquarters of the diabetes business, did not have an adequate quality system in the areas of risk assessment, corrective and preventive actions, complaint handling, device recalls and adverse event reporting.
Needless to say, the bad news has lowered the stock price. When Martha joined the company in April 2020, the share price was around $95. By July 2021, it had climbed to $133. On Monday afternoon, it closed at $105.61.
Earlier in the day, Martha took responsibility for the failures and confronted them head-on in his prepared remarks.
“I am disappointed and angry and deeply responsible for it,” he said.
In addition to the above, Medtronic has also been forced to deal with numerous recalls, including insulin pumps and other equipment, which include class i remember Identify FDA’s most severe recall categories.
Why Medtronic just bought Affera
Ahead of his presentation, Medtronic announced it was acquiring Boston-based take it, a cardiac ablation company worth $925 million despite a $250 million contingency. Cardiac ablation is used to treat atrial fibrillation, an irregular heart rhythm that causes palpitations, shortness of breath, and fatigue. In prepared remarks, Martha said the first access to cardiac mapping and navigation technology through Affera Medtronic makes it more competitive with competitors’ products.
During the Q&A session, JPMorgan analyst Robbie Marcus asked Martha to explain the rationale behind the acquisition, since Medtronic already has another pulsed field ablation technology. Martha replied:
Look, AFIB is a huge market, it’s growing, and we have some great treatments, but we have a gap — we have a gap in map navigation, and that’s an important gap that we want to fill. This is an important part of the program. That’s a big part of the clinical side, a big part of the economic side, and we think Affera fills that gap, it gives us a best-in-class system. On the PFA side (pulsed field ablation), I think they have this focal catheter, which is a very complementary product to our existing products.
Most businesses see financial recovery
Many of Medtronic’s devices are associated with elective surgeries affected by Covid-19. But while it’s too early to determine how Omicron will impact the business, Martha shared some information that will inspire any executives dreaming of a return to more stable economic times.
“Fourteen of our 20 businesses had revenue levels last quarter at or above pre-pandemic levels two years ago,” Marth said.
While that’s good news, Martha did add that the recovery in the U.S. and Europe will take longer due to staffing shortages. Staffing shortages are a pain nearly every other business is currently facing, and that pain is likely to intensify given the transmissibility of the Omicron variants that are currently actively circulating.
Some Medtronic businesses are on the chopping block
Medtronic has undergone dramatic changes under Martha, and operationally it appears to have reverted to the decentralized structure that former chief executive Omar Ishraq avoided for the group’s business model.
Under this model, Medtronic has 20 separate businesses compared to the four core group businesses of the past.
But that’s not the only change Martha has spearheaded. Marcus pressed him about what Medtronic’s “portfolio review” meant and which businesses were at risk of being axed.
However, Martha was coy.
No, no, I don’t want to go into those details, but yes, it’s more front and center. The initial focus was on the 20 operating units and cultural change that really drove us to innovate faster.Now we’re moving into a field that’s more focused on some fundamental things like operational excellence, end-to-end supply chain and quality… from new insights [operating] Models really help us provide [info] About what it takes to win, what are the market opportunities, what are the dynamics, what are the challenges. This gives us an insight into our portfolio analysis.I’d be surprised if nothing changes over the next year, but if they’re big, if they’re on the fringes and we’re not really ready to get into that, which merchants we wouldn’t order right now [will be cut.]
Photo: Medtronic
